Idiopathic inflammatory myopathies related lung disease in adults
- PMID: 39622261
- DOI: 10.1016/S2213-2600(24)00267-4
Idiopathic inflammatory myopathies related lung disease in adults
Abstract
Interstitial lung disease (ILD) is common in idiopathic inflammatory myopathies in adults, especially in patients with antisynthetase syndrome and anti-MDA5 antibody-associated dermatomyositis. Pulmonary manifestations can range from subclinical ILD to rapidly progressive respiratory failure. Coexistent myositis, characteristic skin lesions, arthritis, and Raynaud's phenomenon are common. However, 16-65% of patients present with isolated lung disease. Detection of myositis-specific and myositis-associated antibodies can aid in diagnosis and disease characterisation. Chest imaging and pathology most commonly show non-specific interstitial pneumonia and organising pneumonia patterns. Immunosuppression is the mainstay of management with aggressive combination treatment for rapidly progressive disease and incremental escalation as needed for chronic ILD. The addition of antifibrotic agents is an option in progressive fibrotic disease, and lung transplantation can be considered in severe, end-stage disease. Most patients respond to treatment, but short-term mortality remains high for patients with rapidly progressive disease associated with anti-MDA5 antibody ILD.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests APF received grants and contracts from Mallinckrodt, Novartis, Corbus, Alexion, Priovant, and Pfizer; consulting fees from Biogen, AbbVie, Novartis, Bristol-Myers Squibb, and UCB; is on the speakers' bureau for AbbVie, Mallinckrodt, Kyowa Kirin, and Novartis; is on the Board of Directors for American Society of Dermatopathology; is the Director at-large for the Rheumatologic Dermatology Society; and is on the OMERACT Shared-Decision Making Committee. YL received consulting fees from Argenx, Immunovant, and UCB; and grant support from Argenx. SKD received grants and contracts from Boehringer Ingelheim and United Therapeutics; is on steering committees for Avalyn and Bristol-Myers Squibb; is an educational speaker (non-branded) for Merck; and received royalties from UpToDate. EMW has grants from the National Institutes of Health (K08AR080808); serves as a consultant for AstraZeneca, Cabaletta Bio, Capstan Therapeutics, and Merck; and receives royalties from UpToDate. KBH received grants or contracts from aTyr Pharmaceuticals, Boehringer Ingelheim, Gossamer Bio, Merck (Acceleron), and United Therapeutics; consulting fees from aTyr Pharmaceuticals, Boehringer Ingelheim, Gossamer Bio, Merck (Acceleron), United Therapeutics, Johnson and Johnson (Actelion, Janssen), and Mistsubishi Pharmaceuticals; is on the speakers' bureau for Bayer Healthcare, Boehringer Ingelheim, Johnson and Johnson (Actelion, Janssen), Merck (Acceleron), and United Therapeutics; is on the steering committee for Boehringer Ingelheim, Gossamer Bio, Johnson and Johnson (Actelion, Janssen), Merck (Acceleron), and United Therapeutics; and is the co-founder of Zafer Therapeutics. RY is an educational speaker for Boehringer Ingelheim. All other authors declare no competing interests.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
